Medication Potential Side effects and Risk Disclosure 

Medication Potential Side effects and Risk Disclosure

Risk Disclosure: Semaglutide

Semaglutide may cause side effects including nausea, vomiting, diarrhea, constipation, and abdominal pain. Serious risks include pancreatitis, gallbladder problems, kidney injury, and allergic reactions. Semaglutide is not recommended for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Use under medical supervision is essential. Inform your provider of all medications and medical conditions before starting treatment.

Risk Disclosure: Tirzepatide

Tirzepatide may cause nausea, vomiting, diarrhea, decreased appetite, and indigestion. Rare but serious side effects include pancreatitis, hypoglycemia (especially when combined with other diabetes medications), and allergic reactions. Patients with a history of thyroid tumors should avoid this medication. Close monitoring by a healthcare provider is required to manage side effects and adjust dosing safely.

Risk Disclosure: NAD+

NAD+ therapy is generally well tolerated, but potential risks include injection site reactions, flushing, dizziness, and headache. Because NAD+ is not FDA-approved for weight loss or metabolic conditions, its long-term safety and effectiveness are not fully established. Use only under the guidance of a healthcare professional experienced in NAD+ therapy.

Risk Disclosure: Sermorelin

Sermorelin may cause side effects such as injection site irritation, headache, flushing, dizziness, and nausea. Rarely, allergic reactions may occur. As a growth hormone–releasing hormone analog, sermorelin should be used cautiously in patients with active cancer or proliferative diseases. Treatment requires medical supervision with regular monitoring.

Important: Always consult your healthcare provider for personalized medical advice. Report any adverse effects immediately, and do not discontinue medications without professional guidance